Home »
Academic Articles & Research Papers
Showing 7 of 7 academic articles
Cockey JR, Zhou GM, Kulp EN, Urbina CA et al. • American journal of veterinary research
(2025)
PMC
PMC Public Access (View-Only)
DOI: 10.2460/ajvr.24.08.0247
PMC: PMC13733618
Ahmad Hasan, Wadi B. Alonazi, Muhammad Ibrahim, Li Bin • Microorganisms
(2024)
Vandammella animalimorsus is a Gram-negative and non-motile bacterium typically transmitted to humans through direct contact with the saliva of infected animals, primarily through biting, scratches, or licks on fractured skin. The absence o...
DOAJ
Open Access (DOAJ)
DOI: 10.3390/microorganisms12071270
Thao Nguyen, Toshiaki Yoshikawa, Yusuke Ito, Hitomi Kasuya et al. • STAR Protocols
(2024)
Summary: Chimeric antigen receptor (CAR) T cell therapy often causes serious toxicities, such as cytokine release syndrome (CRS), mainly due to interleukin-6 (IL-6) secreted by monocyte lineage cells. Here, we describe a protocol to generat...
DOAJ
Open Access (DOAJ)
DOI: 10.1016/j.xpro.2024.103423
Wei Liu, Yan Xu, Yi Wang, Lugui Qiu et al. • Journal for ImmunoTherapy of Cancer
(2024)
Background Over 50% of patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) receiving CD19-targeted chimeric antigen receptor (CAR19) T-cell therapy fail to achieve durable remission. Early identification of relapse or prog...
DOAJ
Open Access (DOAJ)
DOI: 10.1136/jitc-2023-008450
Katie S. Gatwood, Bhagirathbhai R. Dholaria, Mariana Lucena, Brittney Baer et al. • eJHaem
(2022)
Abstract Adoptive cellular therapy has made a landmark change within the treatment paradigm of several hematologic malignancies, and novel cellular therapy products, such as chimeric antigen receptor T‐cell therapy (CART), have demonstrated...
DOAJ
Open Access (DOAJ)
DOI: 10.1002/jha2.333
Safwaan H. Khan, Safwaan H. Khan, Yeonjoo Choi, Mysore Veena et al. • Frontiers in Immunology
(2025)
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of hematologic malignancies, achieving remarkable clinical success with FDA-approved therapies targeting CD19 and BCMA. However, the extension of these successe...
DOAJ
Open Access (DOAJ)
DOI: 10.3389/fimmu.2024.1489827
Katharina Schindler, Katharina Eva Ruppel, Claudia Müller, Ulrike Koehl et al. • Molecular Therapy: Methods & Clinical Development
(2024)
Chimeric antigen receptor (CAR) T cell therapies have demonstrated significant successes in treating cancer. Currently, there are six approved CAR T cell products available on the market that target different malignancies of the B cell line...
DOAJ
Open Access (DOAJ)
DOI: 10.1016/j.omtm.2024.101328